Fermenta Biotech Announces INR 110 Crore Expansion of Its Dahej Facility

(Image: DhruvStar Industry Insights | Original Artwork)

Fermenta Biotech has approved an INR 110 crore investment to expand its Dahej facility. The company aims to expand its footprint in plant-based Vitamin D3, its derivatives, and green chemistry enzymes - areas where global demand is rising.

Read More: BIRSA 101 Gene Therapy

What the Expansion Covers

The investment targets three specialised manufacturing streams:

• Plant-based Vitamin D3
• Vitamin D3 derivatives
• Green chemistry enzymes

Vitamin D3 (cholecalciferol) and its derivatives are used to support bone health, immune function, blood pressure management, overall health & weight management, among others.

Green chemistry enzymes enable the sustainable, cleaner production of essential pharmaceuticals and supplements. They reduce the need for hazardous organic solvents, high temperatures, and high pressures.

Read More: India International Science Festival 2025

Implementation Timeline

The planned rollout will occur across two fiscal years: FY26 (2025-26) and FY27 (2026-27). This phased implementation suggests alignment of capacity with market demand.

Read More: Expansion of Sustainable Biomanufacturing Capacity at Concordia University

Why This Matters

The expansion strengthens Fermenta Biotech’s positioning in:

• Alternative and plant-based nutraceutical ingredients
• Speciality enzyme markets driven by green chemistry adoption
• Value-added derivatives with export potential

For a mid-sized biotech player, committing INR 110 crore indicates long-term confidence in specialised, innovation-led biotech product lines.

Read More: Achievements of the Department of Biotechnology (DBT) in 2025

DhruvStar Industry Insights: What It Means for the Biotechnology Sector

1) Rising Demand for Niche Bio-Ingredients

The move reflects an increase in environmentally conscious global demand for plant-based molecules and speciality enzymes, creating opportunities for Indian firms to scale.

2) Scope for Mid-Sized Biotech Players

Targeted investments in high-value segments show how mid-tier biotechnology firms can compete internationally through specialisation rather than scale.

3) Shift Toward Sustainable Manufacturing

Green chemistry enzymes highlight the industry’s transition toward lower-waste, energy-efficient production methods.

Sources

[1] ScanX

Contact: dhruvstar.research@gmail.com